CD40LG and Miyoshi myopathy: In a multicenter analysis from the CIBMTR, Reece et al. showed that patients with IgM MM had 3-year progression-free and overall survival rates of 47% and 68%, respectively—outcomes comparable to IgG and IgA myeloma, underscoring that ASCT is a viable option for IgM MM patients [35].